A real-world assessment links severe hypoglycemia and impaired awareness to lower quality of life in continuous glucose monitoring (CGM) users, reframing how clinicians evaluate CGM benefits beyond glucose metrics. The report describes reduced quality-of-life scores among CGM patients who experience severe events and diminished awareness, suggesting that CGM adoption does not automatically resolve patient burden. The finding highlights that patient-level outcomes depend on hypoglycemia history and behavioral/physiological adaptation. It also suggests that CGM programs may require targeted education and hypoglycemia risk management to translate technology into lived improvements. For product teams and payers, the message is to incorporate quality-of-life endpoints when benchmarking real-world CGM performance.